Literature DB >> 11051140

Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.

K Shono1, T Tajiri, Y Fujii, S Suita.   

Abstract

PURPOSE: In patients with neuroblastoma (NB), minimal disease (MD) in bone marrow (BM) and peripheral blood (PB) is thought to play an important role in metastasis. The current study was designed to evaluate the clinical implications of the detection of MD in NB at the initial diagnosis.
METHODS: Expression of the neuroendocrine protein gene product 9.5 (PGP9.5) and tyrosine hydroxylase (TH) mRNA in BM and PB obtained from 18 patients with NB was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: MD was detected in the BM obtained from 4 of 14 localized NB patients and also in the PB from 2. However, it was found also in both the BM and PB obtained from all 4 patients with metastatic NB. Two of the 4 MD-positive patients with localized NB had metastatic recurrence after a complete tumor excision. They also had unfavorable biological prognostic factors compared with the other 2 who did not have recurrent disease.
CONCLUSION: MD detected by RT-PCR in the BM and the PB of patients with NB thus suggests a risk for metastatic disease, which in association with other unfavorable biological features may indicate a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051140     DOI: 10.1053/jpsu.2000.16403

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

Review 1.  Micrometastases in neuroblastoma: are they clinically important?

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

2.  Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow.

Authors:  S N Bomken; K Redfern; K M Wood; M M Reid; D A Tweddle
Journal:  J Clin Pathol       Date:  2006-03-24       Impact factor: 3.411

3.  Morphologic alteration of metastatic neuroblastic tumor in bone marrow after chemotherapy.

Authors:  Go Eun Bae; Yeon-Lim Suh; Ki Woong Sung; Jung-Sun Kim
Journal:  Korean J Pathol       Date:  2013-10-25

4.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.